The proposed bill would amend current statutes regarding the expenditure of public funds for health insurance coverage by replacing the term "expend" with "spend" in sections 38-651 and 38-651.01. It would also clarify that public monies cannot be spent on genetic sequencing procedures performed using devices produced by companies domiciled in foreign adversaries or those owned or substantially controlled by such companies. This new prohibition is aimed at enhancing national security by restricting funding to entities that may pose a risk.

Additionally, the bill introduces definitions for key terms such as "company," "domiciled," "foreign adversary," and "genetic sequencing," which are intended to provide clarity on the scope of the prohibitions. The definition of "foreign adversary" includes specific countries and entities under significant control of these nations. The bill also makes various technical and conforming changes to ensure consistency throughout the statutes. Overall, these updates aim to strengthen the regulations surrounding the use of public funds in relation to health insurance and genetic sequencing.

Statutes affected:
Introduced Version: 38-651, 38-651.01, 38-1114, 38-1141, 38-652, 15-388, 15-187.01, 38-656
House Engrossed Version: 38-651, 38-651.01, 38-1114, 38-1141, 38-652, 15-388, 15-187.01, 38-656